Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study

Creative Commons License

Taher A. T., Cappellini M. D., Aydınok Y., Porter J. B., Karakas Z., Viprakasit V., ...Daha Fazla

BLOOD CELLS MOLECULES AND DISEASES, cilt.57, ss.23-29, 2016 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.bcmd.2015.11.002
  • Dergi Adı: BLOOD CELLS MOLECULES AND DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.23-29
  • Anahtar Kelimeler: Non-transfusion-dependent thalassaemia, NTDT, Iron overload, Iron chelation therapy, Dose escalation, SERUM FERRITIN, OVERLOAD, DEFERIPRONE, MORBIDITY
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi Adresli: Evet

Özet

Efficacy and safety of iron chelation therapy with deferasirox in iron-overloaded non-transfusion-dependent thalassaemia (NTDT) patients were established in the THALASSA study. THETIS, an open-label, single-arm, multicentre, Phase IV study, added to this evidence by investigating earlier dose escalation by baseline liver iron concentration (LIC) (week 4: escalation according to baseline LIC; week 24: adjustment according to LIC response, maximum 30 mg/kg/day). The primary efficacy endpoint was absolute change in LIC from baseline to week 52. 134 iron-overloaded non-transfusion-dependent anaemia patients were enrolled and received deferasirox starting at 10 mg/kg/day. Mean actual dose +/- SD over 1 year was 14.70 +/- 5.48 mg/kg/day. At week 52, mean LIC SD decreased significantly from 15.13 +/- 10.72 mg Fe/g dw at baseline to 8.46 +/- 6.25 mg Fe/g dw (absolute change from baseline, -6.68 +/- 7.02 mg Fe/g dw [95% CI: -7.91, -5.45]; P<0.0001). Most common drug-related adverse events were gastrointestinal: abdominal discomfort, diarrhoea and nausea (n = 6 each). There was one death (pneumonia, not considered drug related). With significant and clinically relevant reductions in iron burden alongside a safety profile similar to that in THALASSA, these data support earlier escalation with higher deferasirox doses in iron-overloaded non-transfusion-dependent anaemia patients. (C) 2015 The Authors. Published by Elsevier Ltd.